We develop personalised cancer treatments that precisely target tumour cells - and at the same time think therapeutically about the tumour environment. Our strength lies in the close integration of clinical, molecular laboratory and data science (including AI-supported molecular tumour boards, liquid biopsy, integrated study platforms). In the EU SARAH consortium, we particularly target patients who have not responded adequately to previous therapies and develop biomarker-based combination therapies.

End of project 1 - GFI1/GFI1B as a driver and target structure

Question: What role do the transcription factors GFI1 and GFI1B play in the development, progression and prognosis of leukaemias/lymphomas - and can they be used therapeutically?
Approach: Functional studies in mouse models and primary material, target validation, derivation of mechanisms of action and targets for new therapies.

Project 2 - Polarisation of stroma

Question: How do malignant cells "reprogram" stromal cells to promote tumour growth - and how can this be reversed?
Approach: Mapping of cell-cell signals, identification of polarising axes, preclinical testing of microenvironment-targeted interventions.

Project 3 - Cytogenetics & epigenetics as levers

Question: How do genetic and epigenetic changes contribute to genome stability and malignancy - and how can this be exploited therapeutically?
Approach: Multi-omics, functional screens, epigenetic modulators; linking with clinical courses for precise risk stratification.

Project 4 - AML, MDS, histiocytosis, advanced malignancies, myeloma & amyloidosis

Question: Which molecular mechanisms drive the diseases - and which therapy sequences improve the course?
Approach: Pathomechanisms, biomarker panels, AI-supported decision models; translation into clinical studies and care.